OTC · EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
Loading market information…
NASDAQ · NTBL · USD
Stock price, earnings
Quote as of Oct 22, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Notable Labs, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Notable Labs, Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:10 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q4 2022 | Mar 14, 2023 | -$1.64+66.53% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$4.93-$0.17 (-3.33%)
Palatin Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.1% below the high.
$0.04-$0.01 (-13.39%)
Aravive, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$0.09-$0.03 (-24.84%)
Novan, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.17% below the high.
$0.09$0.00 (0.0%)
PLx Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.45% below the high.
$0.20$0.00 (0.0%)
Athenex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.15% below the high.
$0.85-$0.26 (-23.42%)
Fresh2 Group Limited’s quoted price sits in the lower half of its reported 52-week range, 90.56% below the high.
$0.29-$0.06 (-18.5%)
Midatech Pharma plc’s quoted price sits in the lower half of its reported 52-week range, 98.63% below the high.
